nach oben

Erschienen in:

22.01.2021 | Research Article

Dynamic Contrast-Enhanced Ultrasound Radiomics for Hepatocellular Carcinoma Recurrence Prediction After Thermal Ablation

verfasst von: Qiu-Ping Ma, Xue-lei He, Kai Li, Jin-fen Wang, Qing-Jing Zeng, Er-Jiao Xu, Xu-qi He, Shuo-yang Li, Wang Kun, Rong-Qin Zheng, Jei Tian

Erschienen in: Molecular Imaging and Biology | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To develop a radiomics model based on dynamic contrast-enhanced ultrasound (CEUS) to predict early and late recurrence in patients with a single HCC lesion ≤ 5 cm in diameter after thermal ablation.

Procedures

We enrolled patients who underwent thermal ablation for HCC in our hospital from April 2004 to April 2017. Radiomics based on two branch convolution recurrent network was utilized to analyze preoperative dynamic CEUS image of HCC lesions to establish CEUS model, in comparison to the conventional ultrasound (US), clinical, and combined models. Clinical follow-up of HCC recurrence after ablation were taken as reference standard to evaluate the predicted performance of CEUS model and other models.

Results

We finally analyzed 318 patients (training cohort: test cohort = 255:63). The combined model showed better performance for early recurrence than CUES (in training cohort, AUC, 0.89 vs. 0.84, P < 0.001; in test cohort, AUC, 0.84 vs. 0.83, P = 0.272), US (P < 0.001), or clinical model (P < 0.001). For late recurrence prediction, the combined model showed the best performance than the CEUS (C-index, in training cohort, 0.77 vs. 0.76, P = 0.009; in test cohort, 0.77 vs. 0.68, P < 0.001), US (P < 0.001), or clinical model (P < 0.001).

Conclusions

The CEUS model based on dynamic CEUS radiomics performed well in predicting early HCC recurrence after ablation. The combined model combining CEUS, US radiomics, and clinical factors could stratify the high risk of late recurrence.

Nur mit Berechtigung zugänglich

J F, I S, R D, S E, C M, M R, DM P, D F, cancer BFJIjo: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. 2015, 136(5):E359–386

Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md) 53(3):1020–1022CrossRef

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018, 69(1):182–236

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012, 56(4):908–943

Benson AB 3rd, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Saenz DA, Are C, Brown DB, Chang DT, Covey AM et al (2017) NCCN Guidelines insights: Hepatobiliary cancers, version 1.2017. J Natl Compr Cancer Network 15(5):563–573CrossRef

Hirokawa F, Hayashi M, Miyamoto Y, Asakuma M, Shimizu T, Komeda K, Inoue Y, Uchiyama K (2014) Outcomes and predictors of microvascular invasion of solitary hepatocellular carcinoma. Hepatol Res 44(8):846–853CrossRef

Renzulli M, Brocchi S, Cucchetti A, Mazzotti F, Mosconi C, Sportoletti C, Brandi G, Pinna AD, Golfieri R (2016) Can current preoperative imaging be used to detect microvascular invasion of hepatocellular carcinoma? Radiology 279(2):432–442CrossRef

Pawlik TM, Gleisner AL, Anders RA, Assumpcao L, Maley W, Choti MA (2007) Preoperative assessment of hepatocellular carcinoma tumor grade using needle biopsy: implications for transplant eligibility. Ann Surg 245(3):435–442CrossRef

Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Carvalho S, Bussink J, Monshouwer R, Haibe-Kains B, Rietveld D et al (2014) Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 5:4006CrossRef

10.

Limkin EJ, Sun R, Dercle L, Zacharaki EI, Robert C, Reuze S, Schernberg A, Paragios N, Deutsch E, Ferte C (2017) Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology. Ann Oncol 28(6):1191–1206CrossRef

11.

Kim S, Shin J, Kim DY, Choi GH, Kim MJ, Choi JY (2019) Radiomics on gadoxetic acid-enhanced magnetic resonance imaging for prediction of postoperative early and late recurrence of single hepatocellular carcinoma. Clin Cancer Res 25(13):3847–3855CrossRef

12.

Yuan C, Wang Z, Gu D, Tian J, Zhao P, Wei J, Yang X, Hao X, Dong D, He N, Sun Y, Gao W, Feng J (2019) Prediction early recurrence of hepatocellular carcinoma eligible for curative ablation using a Radiomics nomogram. Cancer Imaging 19(1):21CrossRef

13.

Zheng BH, Liu LZ, Zhang ZZ, Shi JY, Dong LQ, Tian LY, Ding ZB, Ji Y, Rao SX, Zhou J, Fan J, Wang XY, Gao Q (2018) Radiomics score: a potential prognostic imaging feature for postoperative survival of solitary HCC patients. BMC Cancer 18(1):1148CrossRef

14.

Hui TCH, Chuah TK, Low HM, Tan CH (2018) Predicting early recurrence of hepatocellular carcinoma with texture analysis of preoperative MRI: a radiomics study. Clin Radiol 73(12):1056.e1011–1056.e1016CrossRef

15.

Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, Chen MH, Choi BI, de Baere T, Dodd GD 3rd et al (2014) Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update. Radiology 273(1):241–260CrossRef

16.

Alzaraa A, Gravante G, Chung WY, Al-Leswas D, Morgan B, Dennison A, Lloyd D (2013) Contrast-enhanced ultrasound in the preoperative, intraoperative and postoperative assessment of liver lesions. Hepatol Res 43(8):809–819CrossRef

17.

Liu F, Liu D, Wang K, Xie X, Su L, Kuang M, Huang G, Peng B, Wang Y, Zhou H: Deep learning radiomics based on contrast-enhanced ultrasound might optimize curative treatments for very early or early stage HCC patients. 2019

18.

Ma QP, Xu EJ, Zeng QJ, Su ZZ, Tan L, Chen JX, Zheng RQ, Li K (2019) Intraprocedural computed tomography/magnetic resonance-contrast-enhanced ultrasound fusion imaging improved thermal ablation effect of hepatocellular carcinoma: comparison with conventional ultrasound. Hepatol Res 49(7):799–809PubMed

19.

J B, M S, Hepatology J: Management of hepatocellular carcinoma. 2005, 42(5):1208–1236

20.

B P, report BAJG: Diagnosis of cirrhosis and portal hypertension: imaging, non-invasive markers of fibrosis and liver biopsy. 2017, 5(2):79–89

21.

JJM vG, A F, C P, A H, N A, V N, RGH B-T, JC F-R, S P, research AHJC: Computational radiomics system to decode the radiographic phenotype. 2017, 77(21):e104-e107

22.

hepatology JZgzbzzZgzCjo: [Diagnosis, management, and treatment of hepatocellular carcinoma (V2017)]. 2017, 25(12):886–895

23.

Roayaie S, Blume IN, Thung SN, Guido M, Fiel MI, Hiotis S, Labow DM, Llovet JM, Schwartz ME (2009) A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology 137(3):850–855CrossRef

24.

Miyata R, Tanimoto A, Wakabayashi G, Shimazu M, Nakatsuka S, Mukai M, Kitajima M (2006) Accuracy of preoperative prediction of microinvasion of portal vein in hepatocellular carcinoma using superparamagnetic iron oxide-enhanced magnetic resonance imaging and computed tomography during hepatic angiography. J Gastroenterol 41(10):987–995CrossRef

25.

Shan QY, Hu HT, Feng ST, Peng ZP, Chen SL, Zhou Q, Li X, Xie XY, Lu MD, Wang W, Kuang M (2019) CT-based peritumoral radiomics signatures to predict early recurrence in hepatocellular carcinoma after curative tumor resection or ablation. Cancer Imaging 19(1):11CrossRef

26.

An C, Kim DW, Park YN, Chung YE, Rhee H, Kim MJ (2015) Single hepatocellular carcinoma: preoperative MR imaging to predict early recurrence after curative resection. Radiology 276(2):433–443CrossRef

27.

Liang JD, Ping XO, Tseng YJ, Huang GT, Lai F, Yang PM (2014) Recurrence predictive models for patients with hepatocellular carcinoma after radiofrequency ablation using support vector machines with feature selection methods. Comput Methods Prog Biomed 117(3):425–434CrossRef

28.

Wu CF, Wu YJ, Liang PC, Wu CH, Peng SF, Chiu HW (2017) Disease-free survival assessment by artificial neural networks for hepatocellular carcinoma patients after radiofrequency ablation. J Formosan Med Assoc 116(10):765–773CrossRef

29.

Rennert J, Georgieva M, Schreyer AG, Jung W, Ross C, Stroszczynski C, Jung EM (2011) Image fusion of contrast enhanced ultrasound (CEUS) with computed tomography (CT) or magnetic resonance imaging (MRI) using volume navigation for detection, characterization and planning of therapeutic interventions of liver tumors. Clin Hemorheol Microcirc 49(1–4):67–81CrossRef

30.

Strobel D, Bernatik T, Blank W, Schuler A, Greis C, Dietrich CF, Seitz K (2011) Diagnostic accuracy of CEUS in the differential diagnosis of small (</= 20 mm) and subcentimetric (</= 10 mm) focal liver lesions in comparison with histology. Results of the DEGUM multicenter trial. Ultraschall Medizin (Stuttgart, Germany : 1980) 32(6):593–597CrossRef

31.

Schoenleber SJ, Kurtz DM, Talwalkar JA, Roberts LR, Gores GJ (2009) Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer 100(9):1385–1392CrossRef

32.

Huang KW, Yang SY, Yu CY, Chieh JJ, Yang CC, Horng HE, Hong CY, Yang HC, Wu CC (2011) Exploration of the relationship between the tumor burden and the concentration of vascular endothelial growth factor in liver-cancer-bearing animals using immunomagnetic reduction assay. J Biomed Nanotechnol 7(4):535–541CrossRef

33.

K S, J S, H T, K T, K A, Y K, H I, Liver MFJLiojotIAftSot: Computer-aided diagnosis for estimating the malignancy grade of hepatocellular carcinoma using contrast-enhanced ultrasound: an ROC observer study. 2016, 36(7):1026–1032

34.

Gao Y, Zheng DY, Cui Z, Ma Y, Liu YZ, Zhang W (2015) Predictive value of quantitative contrast-enhanced ultrasound in hepatocellular carcinoma recurrence after ablation. World J Gastroenterol 21(36):10418–10426CrossRef

35.

Tian H, Wang Q (2016) Quantitative analysis of microcirculation blood perfusion in patients with hepatocellular carcinoma before and after transcatheter arterial chemoembolisation using contrast-enhanced ultrasound. Eur J Cancer (Oxford, England : 1990) 68:82–89CrossRef

36.

Zhuang PH, Xu L, Gao L, Lu W, Ruan LT, Yang J (2017) Correlations of microvascular blood flow of contrast-enhanced ultrasound and HGF/c-met signaling pathway with clinicopathological features and prognosis of patients with hepatocellular carcinoma. OncoTargets Ther 10:847–857CrossRef

37.

Floriani I, Torri V, Rulli E, Garavaglia D, Compagnoni A, Salvolini L, Giovagnoni A (2010) Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis. J Magn Reson Imaging 31(1):19–31CrossRef

38.

Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA (2011) Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology (Baltimore, Md) 54(2):463–471CrossRef

39.

M K, K U, Y O, M H, Y I, K A, K N, M K, T K, N I et al: B-mode ultrasonography versus contrast-enhanced ultrasonography for surveillance of hepatocellular carcinoma: a prospective multicenter randomized controlled trial. 2019, 8(4):271–280

40.

Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, Sugawara Y, Minagawa M, Takayama T, Kawasaki S, Makuuchi M (2003) Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 38(2):200–207CrossRef

41.

Poon RT (2009) Differentiating early and late recurrences after resection of HCC in cirrhotic patients: implications on surveillance, prevention, and treatment strategies. Ann Surg Oncol 16(4):792–794CrossRef

42.

Hayashi M, Shimizu T, Hirokawa F, Inoue Y, Komeda K, Asakuma M, Miyamoto Y, Takeshita A, Shibayama Y, Tanigawa N (2011) Clinicopathological risk factors for recurrence within one year after initial hepatectomy for hepatocellular carcinoma. Am Surg 77(5):572–578CrossRef

43.

Ziol M, Sutton A, Calderaro J, Barget N, Aout M, Leroy V, Blanc JF, Sturm N, Bioulac-Sage P, Nahon P, Nault JC, Charnaux N, N’Kontchou G, Trinchet JC, Delehedde M, Seror O, Beaugrand M, Vicaut E, Ganne-Carrié N (2013) ESM-1 expression in stromal cells is predictive of recurrence after radiofrequency ablation in early hepatocellular carcinoma. J Hepatol 59(6):1264–1270CrossRef

Titel: Dynamic Contrast-Enhanced Ultrasound Radiomics for Hepatocellular Carcinoma Recurrence Prediction After Thermal Ablation
verfasst von: Qiu-Ping Ma
Xue-lei He
Kai Li
Jin-fen Wang
Qing-Jing Zeng
Er-Jiao Xu
Xu-qi He
Shuo-yang Li
Wang Kun
Rong-Qin Zheng
Jei Tian
Publikationsdatum: 22.01.2021
Verlag: Springer International Publishing
Erschienen in: Molecular Imaging and Biology / Ausgabe 4/2021
Print ISSN: 1536-1632
Elektronische ISSN: 1860-2002
DOI: https://doi.org/10.1007/s11307-021-01578-0

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Dynamic Contrast-Enhanced Ultrasound Radiomics for Hepatocellular Carcinoma Recurrence Prediction After Thermal Ablation